GlassScriptPhysician profile
Melissa K Le
NPI 1275846503
$6,462.06
in general payments reported to CMS, 2019-2025
25 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $60.77 · 2021: $394 · 2022: $1,167 · 2023: $803 · 2024: $2,019 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,144 · Travel and Lodging: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,143.68 |
| Travel and Lodging | $907.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,400.43 | 2019-2025 | Rocklatan, Dailies Total1, Simbrinza |
| Johnson & Johnson Vision Care, INC. | $1,055.53 | 2019-2024 | Acuvue |
| Abbvie INC. | $707.36 | 2022-2025 | |
| Allergan, INC. | $369.83 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $285.98 | 2021-2025 | Cequa |
| Coopervision INC. | $219.87 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $177.29 | 2025 | Idosetr, Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Dompe US, INC. | $167.98 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $166.96 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $163.69 | 2019 | |
| Oyster Point Pharma, INC. | $162.99 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $135.79 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $115.17 | 2022 | |
| Bausch & Lomb Americas INC. | $52.07 | 2023-2025 | Xiidra, Miebo, Prolensa |
| Novartis Pharmaceuticals Corporation | $42.12 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $39.32 | 2019 | |
| Astellas Pharma US INC | $33.13 | 2023 | |
| Ocular Therapeutix, INC. | $28.43 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.96 | 2020 | |
| Eyevance Pharmaceuticals LLC | $23.41 | 2022 | |
| Thea Pharma INC. | $22.84 | 2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $21.49 | 2019 | |
| Amgen INC. | $20.84 | 2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $12.99 | 2019 | |
| Abb Con-Cise Optical Group LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.